Chinese Medical Sciences Journal ›› 2020, Vol. 35 ›› Issue (4): 377-382.doi: 10.24920/003799
• Case Report • Previous Articles Next Articles
Xiaoqi Zeng1, Shanshan Jiang2, Yuanyang Peng1, Minfeng Liu1, Changsheng Ye1, Jianyu Dong1, *()
Accepted:
2020-07-17
Published:
2020-12-31
Online:
2021-01-08
Contact:
Jianyu Dong
E-mail:djypumc@163.com
Xiaoqi Zeng, Shanshan Jiang, Yuanyang Peng, Minfeng Liu, Changsheng Ye, Jianyu Dong. Trastuzumab-Induced Severe Thrombocytopenia:A Case Report and Literature Review[J].Chinese Medical Sciences Journal, 2020, 35(4): 377-382.
Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks
Table 1
Clinical information of the trastuzumab-induced thrombocytopenia cases reported in the literature"
Case No. | References | Year* | Age (y/o) | Cycle | Onset time | Symptom (s) | Platelet# (×109/L) | Treatment | Recovery time |
---|---|---|---|---|---|---|---|---|---|
1 | Cathomas R, et al.[ | 2007 | 54 | 1 | 4 days | Nose bleeding and petechiae | 3 | Immunoglobulin; methylprednisolone | 7 days |
2 | Parikh O, et al.[ | 2006 | 56 | 1 | 10 hours | Petechiae | 2 | Immunoglobulin | 7 days |
3 | Jara Sanchez C. et al.[ | 2008 | 37 | 1 | 1 day | Petechiae | 3 | Gamma globulin; glucocorticoids; SDP transfusion | 4 days |
2 | 3 days | Petechiae | 12 | Splenectomy; glucocorticoids | 7 days | ||||
4 | Drudi F, et al.[ | 2010 | NR | 1 | 19 days | Petechiae | 7 | Immunoglobulin; dexamethasone; SDP transfusion | Death? |
5 | Mantzourani M, et al.[ | 2010 | 56 | 1 | 3 days | Nose bleeding and petechiae | 5 | Immunoglobulin | 5 days |
2 | 3 days | NR | 28 | NR | 10 days | ||||
3 | 3 days | NR | 128 | NR | N/A | ||||
6 | Pino MS, et al.[ | 2012 | 70 | 1 | 1 day | Petechiae and ecchymosis | 0 | Immunoglobulin; methylprednisolone; SDP transfusion | 6 days |
7 | Zeng RC, et al.[ | 2010 | 57 | 2 | 5 days | Tiredness | 28 | Ethamsylate? | 7 days |
3 | 4 days | None | 19 | Ethamsylate; rhTPO | 9 days | ||||
4 | 4 days | None | 39 | rhTPO | 8 days | ||||
5 | 1 day | Tiredness and dental bleeding | 20 | Ethamsylate | 8 days | ||||
6 | N/A | None | Normal | N/A | N/A | ||||
7 | 3 days | Dental bleeding | 60 | Ethamsylate | 8 days | ||||
8 | 1 day | Dental bleeding | 39 | Ethamsylate | 10 days | ||||
8 | Miarons M, et al. [ | 2015 | 70 | 4 | NR | None | 39 | Prednisone | 4 weeks |
9 | Luo Q, et al.[ | 2016 | 39 | 1 | 10 days | Petechiae | 3 | SDP transfusion; ethamsylate; IL-11 | 5 days |
2 | 7 hours | Petechiae | 9 | Gamma globulin; SDP transfusion; ethamsylate; IL-11 | 4 days | ||||
10 | Current case | 2019 | 29 | 1 | 21 days | None | 74 | Observation | N/A |
2 | 6 hours | Uterine bleeding | 3 | Oxytocin; SDP transfusion; dexamethasone; IL-11; rhTPO | 11 days |
1. |
Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6):394-424. doi: 10.3322/caac.21492. PubMed PMID: 30207593.
pmid: 30207593 |
2. | Feng RM, Zong YN, Cao SM, et al. Current cancer situation in China: good or bad news from the 2018 Global Cancer Statistics? Cancer Commun (Lond) 2019; 39(1):22. doi: 10.1186/s40880-019-0368-6. |
3. |
Guo J, Li Q, Zhang P, et al. Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A real-world retrospective study in Chinese patients. Chin J Cancer Res 2019; 31(5):759-70. doi: 10.21147/j.issn.1000-9604.2019.05.06.
doi: 10.21147/j.issn.1000-9604.2019.05.06 pmid: 31814680 |
4. |
Hudis CA. Trastuzumab: mechanism of action and use in clinical practice. N Engl J Med 2007; 357(1):39-51. doi: 10.1056/NEJMra043186.
pmid: 17611206 |
5. |
Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. The Lancet 2017; 389(10075):1195-205. doi: 10.1016/s0140-6736(16)32616-2.
doi: 10.1016/S0140-6736(16)32616-2 |
6. |
Cathomas R, von Moos R. Severe drug-induced thrombocytopenia after treatment with trastuzumab but not with lapatinib. Ann Oncol 2009; 20(9):1606-7. doi: 10.1093/annonc/mdp370.
doi: 10.1093/annonc/mdp370 pmid: 19622591 |
7. | Parikh O, Neave F, Palmieri C. Severe thrombocytopenia induced by a single infusion of trastuzumab. Clin Br Cancer 2008; 8(3):285-6. doi: 10.3816/CBC.2008.n.034. |
8. |
Jara Sanchez C, Olier Garate C, Garcia-Donas Jimenez J, et al. Drug-induced thrombocytopenia induced by trastuzumab: a special challenge in a curable disease. Ann Oncol 2009; 20(9):1607-8. doi: 10.1093/annonc/mdp374.
doi: 10.1093/annonc/mdp374 pmid: 19633054 |
9. |
Drudi F, Gianni L, Fantini M, et al. Trastuzumab-related thrombocytopenia: always a self-limiting complication? Ann Oncol 2010; 21(3):668-9. doi: 10.1093/annonc/mdp566.
doi: 10.1093/annonc/mdp566 pmid: 20032121 |
10. |
Mantzourani M, Gogas H, Katsandris A, et al. Severe thrombocytopenia related to trastuzumab infusion. Med Sci Monit 2011; 17(7):CS85-7.
doi: 10.12659/msm.881846 pmid: 21709629 |
11. |
Pino MS, Angiolini C, Fioretto L. Severe thrombocytopenia after trastuzumab retreatment: a case report. BMC Res Notes 2013; 6:400. doi: 10.1186/1756-0500-6-400.
doi: 10.1186/1756-0500-6-400 pmid: 24093447 |
12. | Zeng RC, Dai XX, Xie FY, et al. Severe thrombocytopenia induced by second exposure to trastuzumab can be alleviated by prolonging the interval between treatments. Clin Br Cancer 2014; 14(2):e69-72. doi: 10.1016/j.clbc.2013.11.004. |
13. |
Miarons M, Velasco M, Campins L, et al. Gradual thrombocytopenia induced by long-term trastuzumab exposure. J Clin Pharm Therapeut 2016; 41(5):563-5. doi: 10.1111/jcpt.12416.
doi: 10.1111/jcpt.12416 |
14. |
Luo Q, Guo Z, Ye C. Thrombocytopenia induced by herceptin. Am Surg 2019; 85(4):e222-4.
pmid: 31043221 |
15. |
George JN, Raskob GE, Shah SR, et al. Drug-induced thrombocytopenia: a systematic review of published case reports. Ann Intern Med 1998; 129(11):886-90.
pmid: 9867731 |
16. |
Aster RH, Bougie DW. Drug-induced immune thrombocytopenia. N Engl J Med 2007; 357(6):580-7. doi: 10.1056/NEJMra066469.
doi: 10.1056/NEJMra066469 pmid: 17687133 |
17. |
Aster RH, Curtis BR, McFarland JG, et al. Drug-induced immune thrombocytopenia: pathogenesis, diagnosis, and management. J Thromb Haemost 2009; 7(6):911-8. doi: 10.1111/j.1538-7836.2009.03360.x.
doi: 10.1111/j.1538-7836.2009.03360.x pmid: 19344362 |
18. |
Neunert C, Terrell DR, Arnold DM, et al. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv 2019; 3(23):3829-66. doi: 10.1182/bloodadvances.2019000966.
doi: 10.1182/bloodadvances.2019000966 pmid: 31794604 |
19. |
Liu XG, Bai XC, Chen FP, et al. Chinese guidelines for treatment of adult primary immune thrombocytopenia. Int J Hematol 2018; 107(6):615-23. doi: 10.1007/s12185-018-2445-z.
doi: 10.1007/s12185-018-2445-z pmid: 29619624 |
[1] | Liu Chao, Chen Xiaoyan, Wu Wenqi, Zhu Xiaofan. A Homozygotic Mutation in KDSR may Cause Keratinization Disorders and Thrombocytopenia: A Case Report [J]. Chinese Medical Sciences Journal, 2020, 35(3): 278-282. |
[2] | Huang He, Lin Ying, Yao Rongxin, He Muqing, Lin Xiaoji. Successful Treatment of Severe Heparin-induced Thrombocytopenia with Intravenous Immunoglobulin, Platelet Transfusion and Rivaroxaban: A Case Report [J]. Chinese Medical Sciences Journal, 2019, 34(1): 60-64. |
[3] | Chen Si, Liu Hong-ju. Emergency Cesarean Delivery in a Parturient with Fontan Circulation and Reduced Platelets: A Case Report [J]. Chinese Medical Sciences Journal, 2017, 32(3): 204-205. |
[4] | Huang Peisen, Yu Yuan, Han Xikun, Yang Yuejin. Efficacy of Short-term Dual Antiplatelet Therapy after Implantation of Second-generation Drug-eluting Stents: A Meta-analysis and Systematic Review [J]. Chinese Medical Sciences Journal, 2017, 32(1): 1-12. |
[5] | Jian-bo Xu, Gang Xu, Guo-feng Chen, Dian-hua Gu, Jian-huai Zhang, Fu-zhen Qi*. Hepatocellular Carcinoma with Hypersplenic Thrombocytopenia and Situs Inversus Totalis: A Case Report [J]. Chinese Medical Sciences Journal, 2016, 31(2): 134-136. |
[6] | Jian-yu Dong, Yan Yan, Min-feng Liu, Zhao-ze Guo, Jing-yun Guo, Chang-sheng Ye. Treatment of Breast Cancer Accompanied by POEMS Syndrome: A Case Report [J]. Chinese Medical Sciences Journal, 2016, 31(1): 59-61. |
[7] | Jin-hua Wen, Xiao-hua Wei, Xiang-yuan Sheng, De-qing Zhou, Hong-wei Peng, Yan-ni Lu, Jian Zhou. Effect of Ursolic Acid on Breast Cancer Resistance Protein-mediated Transport of Rosuvastatin In Vivo and Vitro [J]. Chinese Medical Sciences Journal, 2015, 30(4): 218-225. |
[8] | Yi Bao*,Ling-juan Ruan, Juan-fen Mo. Low Trichorhinophalangeal Syndrome 1 Gene Transcript Levels in Basal-like Breast Cancer Associate with Mesenchymal-to-epithelial Transition [J]. Chinese Medical Sciences Journal, 2013, 28(3): 129-134. |
[9] | Yan Lv?*, Yun Niu, Xiu-min Ding, Xu-qi Xiao. Oncogenic Role of Skp2 and p27Kip1 in Intraductal Proliferative Lesions of the Breast△ [J]. Chinese Medical Sciences Journal, 2012, 27(3): 161-166. |
[10] | Bo Jin*, Yan-ping Liu, Hai-jiang Wang, and Qi-shan Wang. Gastric Metastasis of Atypical Medullary Carcinoma from Breast: a Case Report [J]. Chinese Medical Sciences Journal, 2012, 27(2): 121-124. |
[11] | Na Liu, Jun-tian Liu and Qiang-zong Zhang. Ellagic acid-induced hypercoagulable state in animals: a potentially useful animal hypercoagulable model for evaluation of anticoagulants [J]. Chinese Medical Sciences Journal, 2010, 25(4): 237-242. |
[12] | Li Peng, Qiang Sun, Zhi-yong Liang, Yi-dong Zhou, Feng Mao and Jing-hong Guan. Pure Mucinous Carcinoma of the Breast: a Clinicopathologic Analysis with 56 Patients [J]. Chinese Medical Sciences Journal, 2010, 25(2): 115-118. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||
|
Supervised by National Health Commission of the People's Republic of China
9 Dongdan Santiao, Dongcheng district, Beijing, 100730 China
Tel: 86-10-65105897 Fax:86-10-65133074
E-mail: cmsj@cams.cn www.cmsj.cams.cn
Copyright © 2018 Chinese Academy of Medical Sciences
All right reserved.
京公安备110402430088 京ICP备06002729号-1